The CD213A1 antibody targets the interleukin-13 receptor subunit alpha-1 (IL-13Rα1), a key component of the type II IL-13 receptor complex. IL-13Rα1 pairs with IL-4Rα to form a heterodimeric receptor that binds IL-13 and IL-4. cytokines central to T helper 2 (Th2)-mediated immune responses. This receptor is implicated in allergic inflammation, asthma, and fibrotic diseases, making it a therapeutic target. CD213A1 antibodies are tools for studying IL-13/IL-4 signaling pathways, often used to block receptor activation or detect expression in immune cells (e.g., B cells, macrophages) and epithelial tissues. Research highlights its role in cancer, as IL-13Rα1 is overexpressed in certain tumors, suggesting utility in targeted therapies or diagnostics. Commercial CD213A1 antibodies enable applications like flow cytometry, immunohistochemistry, and functional assays. Current studies focus on modulating IL-13Rα1 activity to treat autoimmune disorders or enhance antitumor immunity, though clinical translation requires further validation of specificity and safety profiles.